Nerviano Medical Sciences SRL provides pharmaceutical services. The company is headquartered in Nerviano, Italy.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Shenlong (Kunshan) Biochemical Technology Co., Ltd., established on 2001-02-13, The scope of business includes the establishment of a research center,develop new drugs,New manufacturing process of raw materials,Formulation,Pharmaceutical Technology,And provide consulting services such as biotechnology research and development;engaged in pharmaceutical raw materials,Pharmaceutical Intermediates,Fine Chemicals,Biochemicals,chemical reagent(medicine,Precursor chemicals and hazardous chemicals are excluded)commercial wholesale,commission agent(except auction)and import and export business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Sunovion Pharmaceuticals Inc. (formerly Sepracor) engages in discovering, developing, and commercializing therapeutic products for patients suffering from central nervous system disorders, respiratory disorders, and other illnesses. Its products include LUNESTA medicine that helps people sleep better; XOPENEX levalbuterol HCl inhalation solution; and BROVANA aformoterol tartrate inhalation solution. The company's products also comprise OMNARIS ciclesonide nasal spray; ALVESCO ciclesonide HFA inhalation aerosol; and LATUDA, an oral antipsychotic tablet for the treatment of schizophrenia. It offers products for the treatment of depression, epilepsy, neuropathic pain, and insomnia, as well as respiratory conditions, such as asthma, allergic rhinitis, and chronic obstructive pulmonary diseases.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

Sunshine Lake Pharma Co. Ltd., a subsidiary of Shenzhen Dongyangguang Industry Co., Ltd., is a Chinese company. The firm manufactures and supplies pharmaceutical ingredients and drugs. Wen Jia Li has been the CEO since 2021. On December 23, 2022 Shenzhen Dongyangguang Industry Co., Ltd. acquired Sunshine Lake Pharma Co. Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd. for $330.99 million.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

Manufactures industrial chemicals

Huls, part of Oranjewoud NV, is a company headquartered in the Netherlands that provides building, maintenance and renovation services. It was acquired by Strukton Bouw & Onderhoud on December 01, 1999.\nThe company says this about itself: HULS is a creative company based in Tokyo and Singapore. Through global website productions, products planning or providing resources and information, we support and help in the overseas expansion of Japanese businesses. We are always on the look out for potential Japanese products/materials manufacturers/ industries for overseas expansion. We are focused on the development of the creative industries in Asia while being centered around Singapore. Under the concept of \"Roots & Touch\", we aim to establish a platform that will bridge across international borders strategically by connecting different cultures and businesses together.

Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Nanjing Ruckus Biomedical Research Co., Ltd., established on 2010-01-04, Business scope includes pharmaceuticals,medical instruments,Health food research and development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Nanjing Ruckus Pharmaceutical Co., Ltd., established on 2003-02-08, The business scope includes freeze-dried powder injection,Freeze-dried powder injection(anticancer drug),small volume injection,small volume injection(non-terminal sterilized),tablet,tablet(anticancer drug),Capsules,Capsules(anticancer drug),Granules,powder injection(Cephalosporins);API(Production according to the scope listed in the license);medicine,Biological Engineering,Healthy food,Technology development of medical devices,to promote,transfer,consultation service;Self-operated and agent import and export business of various commodities and technologies(Except for goods and technologies that are restricted by the state to operate or prohibited from importing and exporting).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Degussa-Hüls AG manufactures and supplies chemical products. It produces industrial chemicals, creavis, iron metal producer, specialty polymers, advanced fillers, performance materials, specialty chemistry, iron and hardening. The company was founded in 1999 and is located in Hanau, Germany.

Guandong Institute of Microbiology is a private company headquartered in Guangzhou, China. The firm operates microbiological research institute.